Estados Unidos · Plataformas y datos · Morningstar

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

Publicado por Morningstar · Estados Unidos hace 16 h

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its…

Leer el artículo completo en Morningstar Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.morningstar.com)

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

También te puede interesar

Looking Beyond the S&P 500? These 2 International ETFs Offer Very Different Opportunities

XY Planning Network Inc. Sells 5,331 Shares of NVIDIA Corporation $NVDA

‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?

Story3 Capital Partners buys $2.25M in Rent the Runway shares

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

Fastenal (FAST) Stock Looks Rich Even After Stronger Earnings

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

Compartir

También te puede interesar

Looking Beyond the S&P 500? These 2 International ETFs Offer Very Different Opportunities

XY Planning Network Inc. Sells 5,331 Shares of NVIDIA Corporation $NVDA

‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?

Story3 Capital Partners buys $2.25M in Rent the Runway shares

Global X Equal Weight Can Insurance Idx ETF declares CAD 0.06 dividend

Fastenal (FAST) Stock Looks Rich Even After Stronger Earnings